SPHK2 and psoriasis: Our findings indicate that psoriasis can be treated by blocking S1P activity by competitively binding to S1PR and inhibiting S1P synthase activity (SPHK2 inhibitor) using a mechanism that is related to decreased immune responses and inflammatory factor levels.